Mental Health Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
European Union's CHMP adopts positive opinion for Suboxone for treatment of opioid dependence
August 28th, 2006
Schering-Plough Corporation (SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has granted a positive opinion recommending approval of Suboxone (buprenorphine hydrochloride/naloxone hydrochloride) Sublingual Tablets for the substitution treatment of opioid dependence, within a framework of medical, social and psychological treatment. Substitution is the treatment approach for opioid dependence in which opiate misuse is replaced with an oral opioid medication such as buprenorphine or methadone. The intention of the naloxone component of Suboxone is to deter intravenous misuse. Suboxone is intended for...
Source: Mental Health Weekly Digest (2006-08-28)
|
